Fanrong Kong

Senior Scientist at Pfizer

Fanrong Kong is a Senior Scientist at Pfizer, with prior experience as a Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson and as a Postdoctoral Fellow at Albert Einstein College of Medicine. Kong's research projects include the expression, purification, and structural determination of the cardiac potassium channel KCNQ1 (Kv7.1) in relation to Long QT Syndrome. Academic qualifications include a Ph.D. in Biology from the Massachusetts Institute of Technology and a Bachelor's Degree in Biological Sciences from Cornell University.

Location

Pearl River, United States

Links


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices


Pfizer

614 followers

Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.